Analysis of Reported Adverse Events for Carmustine Delivered Systematically versus Locally by Gliadel for Malignant Brain Tumors

Carmustine and Carmustine-loaded Gliadel wafers are two chemotherapeutic treatments commonly used in the management of malignant brain tumors, differing primarily in their methods of drug delivery. These two treatment methods use the same chemotherapeutic agent. However, while systemic Carmustine involves widespread distribution, Gliadel wafers provide localized treatment directly at the tumor site, potentially reducing systemic toxicity. This study aims to compare the adverse effect profiles of Carmustine and Gliadel to evaluate differences in safety and clinical risk. The data were primarily taken from the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database. Several important findings were identified, such as the significant difference between the adverse effects of the two drugs. For example, Carmustine displayed a significantly lower percentage of neurologically related adverse effects than Gliadel, but a significantly higher percentage for systemic adverse effects. These systemic effects include bone marrow, hematologic and lymphatic abnormalities. These findings support the conclusion that Carmustine can lead to severe systemic toxicity, while Gliadel is more frequently associated with localized infections and swelling in the brain region.